• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2型糖尿病的预防:最新进展

Prevention of type 2 diabetes: an update.

作者信息

Farag Amal, Karam Jocelyne, Nicasio John, McFarlane Samy I

机构信息

Division of Endocrinology, Veterans Administration, New York Harbor Healthcare System, 800 Poly Place, Brooklyn, NY 11209, USA.

出版信息

Curr Diab Rep. 2007 Jun;7(3):200-7. doi: 10.1007/s11892-007-0032-4.

DOI:10.1007/s11892-007-0032-4
PMID:17547837
Abstract

With the rising tide of the diabetes epidemic leading to increased morbidity and mortality (primarily from cardiovascular disease), together with failure to control the disease and its associated complications, prevention of diabetes appears to be the logical option for curbing this epidemic. Several trials have been completed, and others ongoing, using various strategies for diabetes prevention. In this review, we provide an update on diabetes prevention strategies, highlighting the rationale behind such interventions, together with an outlook of the ongoing efforts that are likely to provide additional options for patients at risk for diabetes.

摘要

随着糖尿病流行趋势的加剧,导致发病率和死亡率上升(主要源于心血管疾病),同时疾病及其相关并发症未能得到控制,预防糖尿病似乎是遏制这一流行趋势的合理选择。已经完成了多项试验,还有其他试验正在进行,采用了各种糖尿病预防策略。在本综述中,我们提供了糖尿病预防策略的最新情况,强调此类干预措施背后的基本原理,以及对正在进行的努力的展望,这些努力可能为糖尿病高危患者提供更多选择。

相似文献

1
Prevention of type 2 diabetes: an update.2型糖尿病的预防:最新进展
Curr Diab Rep. 2007 Jun;7(3):200-7. doi: 10.1007/s11892-007-0032-4.
2
Diabetes prevention programs.糖尿病预防计划。
Med Clin North Am. 2011 Mar;95(2):353-72, viii. doi: 10.1016/j.mcna.2010.11.006.
3
Prevention of type 2 DM: implications for adolescents and young adults.2型糖尿病的预防:对青少年和青年的影响
Pediatr Endocrinol Rev. 2008 Aug;5 Suppl 4:980-8.
4
The prevention of type 2 diabetes.2型糖尿病的预防。
Nat Clin Pract Endocrinol Metab. 2008 Jul;4(7):382-93. doi: 10.1038/ncpendmet0843. Epub 2008 May 20.
5
The prevention of type 2 diabetes mellitus: recent advances.2型糖尿病的预防:最新进展
QJM. 2004 Jul;97(7):451-5. doi: 10.1093/qjmed/hch077.
6
Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes.当前和新兴的用于糖尿病前期和糖尿病患者体重管理的药物治疗。
Can J Diabetes. 2015 Dec;39 Suppl 5:S134-41. doi: 10.1016/j.jcjd.2015.10.001.
7
The early treatment of type 2 diabetes.2 型糖尿病的早期治疗。
Am J Med. 2013 Sep;126(9 Suppl 1):S2-9. doi: 10.1016/j.amjmed.2013.06.007.
8
[Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].[迈向2型糖尿病一级预防的步骤。各种流行病学考量]
Invest Clin. 1997 Mar;38(1):39-52.
9
Prevention of type 2 diabetes.
Curr Diab Rep. 2003 Jun;3(3):235-41. doi: 10.1007/s11892-003-0070-5.
10
Incorporating practical lifestyle management for obesity.纳入针对肥胖的实用生活方式管理。
J Fam Pract. 2010 May;59(5 Suppl):S3-8.

引用本文的文献

1
Effects of Lifestyle Modifications and Dietary Habits on Prevention of Diabetes and Cardiovascular Disease.生活方式改变和饮食习惯对预防糖尿病和心血管疾病的影响。
J Diabetes Res. 2018 Dec 11;2018:2341230. doi: 10.1155/2018/2341230. eCollection 2018.
2
Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM).2 型糖尿病(T2DM)的预防和当前发病延迟方法。
Eur J Clin Pharmacol. 2011 Jul;67(7):653-61. doi: 10.1007/s00228-011-1038-z. Epub 2011 Apr 6.
3
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP).

本文引用的文献

1
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.利莫那班治疗超重或肥胖2型糖尿病患者的疗效及耐受性:一项随机对照研究
Lancet. 2006 Nov 11;368(9548):1660-72. doi: 10.1016/S0140-6736(06)69571-8.
2
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.用于糖耐量受损或空腹血糖受损人群的α-葡萄糖苷酶抑制剂。
Cochrane Database Syst Rev. 2006 Oct 18(4):CD005061. doi: 10.1002/14651858.CD005061.pub2.
3
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
比较慢性肾脏病流行病学协作组(CKD-EPI)和肾脏疾病饮食改良研究(MDRD)方程:肾脏早期评估计划(KEEP)中慢性肾脏病中糖尿病的患病率和危险因素。
Am J Kidney Dis. 2011 Mar;57(3 Suppl 2):S24-31. doi: 10.1053/j.ajkd.2010.11.009.
4
Update on the prevention of type 2 diabetes.2 型糖尿病预防的最新进展。
Curr Diab Rep. 2011 Feb;11(1):56-63. doi: 10.1007/s11892-010-0163-x.
5
Antidiabetic medications and weight gain: implications for the practicing physician.
Curr Diab Rep. 2009 Jun;9(3):249-54. doi: 10.1007/s11892-009-0040-7.
6
Inhibition of the RAS and prevention of diabetes and CVD: mechanistic insights and lessons learned from clinical trials.
Curr Diab Rep. 2009 Feb;9(1):1-3. doi: 10.1007/s11892-009-0001-1.
罗格列酮对糖耐量受损或空腹血糖受损患者糖尿病发生频率的影响:一项随机对照试验。
Lancet. 2006 Sep 23;368(9541):1096-105. doi: 10.1016/S0140-6736(06)69420-8.
4
Effect of ramipril on the incidence of diabetes.雷米普利对糖尿病发病率的影响。
N Engl J Med. 2006 Oct 12;355(15):1551-62. doi: 10.1056/NEJMoa065061. Epub 2006 Sep 15.
5
Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.使用联合疗法预防2型糖尿病:加拿大血糖正常结果评估(CANOE)试验的设计与方法
Diabetes Obes Metab. 2006 Sep;8(5):531-7. doi: 10.1111/j.1463-1326.2005.00540.x.
6
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.大麻素-1受体阻滞剂利莫那班对超重或肥胖患者体重及心血管代谢危险因素的影响:北美RIO研究:一项随机对照试验。
JAMA. 2006 Feb 15;295(7):761-75. doi: 10.1001/jama.295.7.761.
7
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.利莫那班对血脂异常超重患者代谢危险因素的影响。
N Engl J Med. 2005 Nov 17;353(20):2121-34. doi: 10.1056/NEJMoa044537.
8
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.2型糖尿病患者大血管事件的二级预防:PROactive研究(吡格列酮大血管事件前瞻性临床试验):一项随机对照试验
Lancet. 2005 Oct 8;366(9493):1279-89. doi: 10.1016/S0140-6736(05)67528-9.
9
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.双重及全过氧化物酶体增殖物激活受体(PPAR)协同激动作用:非诺贝特的经验教训
Cardiovasc Diabetol. 2005 Sep 16;4:14. doi: 10.1186/1475-2840-4-14.
10
The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes.血管紧张素转换酶抑制剂或血管紧张素II 1型受体阻滞剂对新发2型糖尿病发生发展的影响。
Diabetes Care. 2005 Sep;28(9):2261-6. doi: 10.2337/diacare.28.9.2261.